LabCorp
LH
$320.99
+0.09%
Labcorp Holdings Inc. is one of the two largest independent clinical laboratory operators in the United States, running roughly 2,000 patient-service centers and offering a portfolio of approximately 5,000 clinical tests that span routine blood and urine screens to complex oncology, genomic, and specialty diagnostics, alongside a Biopharma Laboratory Services arm that supports drug development for pharmaceutical and biotech clients. The company sits at the center of the healthcare diagnostics industry, where scale, logistics density, payer contracts, and test-menu breadth create meaningful barriers to entry and a durable duopoly dynamic with its primary national competitor. The current investor narrative centers on the company's aggressive push into AI and robotics to drive operational efficiency, a strategy management has highlighted alongside a strong Q1 earnings beat and raised full-year guidance, which has helped re-rate the stock through 2026. At the same time, debate persists around the sustainability of margin expansion, the drag from lower-margin COVID-era testing comparisons, and whether the biopharma research segment can offset softer routine diagnostics volume trends, making execution on cost automation and specialty-test mix the key swing factors for the equity story.…
LH
LabCorp
$320.99
Related headlines
Investment Opinion: Should I buy LH Today?
Rating: Buy. Labcorp offers a favorable risk/reward for patient investors, anchored by a clear earnings inflection (Q1 2026 net income +30.5% YoY), a forward PE of 16.17x that is 32% below the trailing 23.80x, and unanimous analyst buy ratings with a $343.31 average target implying 7.0% upside. The core thesis is that AI and robotics investments will drive sustainable operating margin expansion, offsetting gross margin pressure and justifying a re-rating toward the upper end of the historical PE band.
Supporting evidence includes: (1) revenue growth of 5.75% YoY in Q1 2026 with stable quarterly cadence around $3.5B; (2) net margin expansion to 7.85% from 6.36% a year earlier, with operating income up 18.8% to $387.2M; (3) trailing free cash flow of $1.384B and a 1.15% dividend yield with a conservative 27.46% payout ratio; and (4) a forward PE of 16.17x versus the 20-25x range for quality healthcare compounders, suggesting the market is discounting execution risk. The PEG ratio of 1.28 indicates the stock is reasonably priced relative to its growth rate.
Key risks that could invalidate the thesis include continued gross margin compression below 26%, a deceleration in revenue growth below 5%, and failure of AI initiatives to deliver margin expansion. The rating would upgrade to a stronger Buy if gross margin stabilizes above 28% and forward EPS estimates are raised, or downgrade to Hold if revenue growth falls below 4% or if the stock breaks below the $306-$307 support level. On valuation, LH appears fairly valued to slightly undervalued relative to its history and peers, with the forward PE discount providing a margin of safety, but the trailing PE of 23.80x is not cheap in absolute terms.
Sign up to view all
LH 12-Month Price Forecast
Labcorp presents a balanced risk/reward with a neutral stance, as the earnings inflection and forward PE discount are offset by gross margin compression and modest revenue growth. The stock's 27.44% YTD gain has already priced in much of the near-term optimism, and the 7.0% upside to the average analyst target suggests limited immediate upside. However, the 16.17x forward PE provides a valuation cushion if the company meets its $25.61 EPS estimate, and the low beta offers downside protection. I would upgrade to bullish if gross margin stabilizes above 28% and operating margin exceeds 11.5%, or downgrade to bearish if revenue growth falls below 4% or if the stock breaks below the $306-$307 support level. The key swing factor is whether AI-driven efficiencies can sustainably expand margins and offset mix-driven gross margin pressure.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LabCorp's 12-month outlook, with a consensus price target around $344.25 and implied upside of +7.3% versus the current price.
Average Target
$344.25
0 analysts
Implied Upside
+7.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$293 - $385
Analyst target range
Labcorp is covered by 16 analysts with a consensus recommendation of "buy" and a recommendation mean of 1.76, reflecting a moderately bullish but not euphoric stance. The average price target is $343.31, which implies roughly 7.0% upside from the current price of $320.71, a modest but positive expected return that aligns with the stock's recent consolidation below its 52-week high. The consensus leans constructive, supported by a string of maintained Outperform and Buy ratings from Baird, B of A Securities, Evercore ISI, JP Morgan, and UBS through 2026, with no downgrades visible in the institutional ratings history. The estimated forward EPS average of $25.61 and revenue estimate of $15.22 billion underpin the bullish case, suggesting analysts expect continued mid-single-digit top-line growth and margin expansion from AI and robotics initiatives. The target range spans $293.00 at the low end to $385.00 at the high end, a spread of roughly $92 or about 30% of the current price, which signals meaningful dispersion in analyst views. The high target of $385 implies roughly 20% upside and likely assumes successful AI-driven margin expansion, specialty-test mix improvement, and multiple re-rating toward the upper end of the historical PE band, while the low target of $293 (about 8.6% downside) appears to price in margin compression, softer diagnostics volumes, or a more conservative earnings multiple. The relatively wide spread, combined with the fact that the average target sits only 7% above the current price, suggests analysts see limited near-term upside but remain constructive on the multi-year earnings trajectory, with the stock's low beta of 0.851 and defensive healthcare characteristics supporting a hold-through-volatility posture for institutional investors.
Bulls vs Bears: LH Investment Factors
The bull case currently has stronger evidence, anchored by a clear earnings inflection (net income +30.5% YoY), a forward PE of 16.17x that is well below the trailing 23.80x, and unanimous analyst buy ratings with a $343.31 average target. The bear case rests on gross margin compression (26.52% in Q1 2026 vs. 29.66% in Q2 2025), lumpy free cash flow, and modest 5.75% revenue growth that limits multiple expansion. The single most important tension is whether the AI and robotics investments can sustainably expand operating margins and offset gross-margin pressure—if they do, the forward PE discount is unjustified and the stock re-rates toward the $385 high target; if they don't, the stock could retest the $293 low target or the $244.52 52-week low. With a beta of 0.851 and a defensive healthcare profile, the risk/reward skews favorably for patient investors, but near-term momentum has stalled and the stock is not cheap on a trailing basis.
Bullish
- Earnings inflection with margin expansion: Q1 2026 net income rose to $277.8M (7.85% net margin) from $212.8M (6.36%) a year earlier, a 30.5% increase, while operating income climbed to $387.2M from $326.0M. This demonstrates that SG&A discipline and automation are translating into bottom-line leverage even as gross margin compressed to 26.52% from 28.77% in Q3 2025.
- Forward PE compression signals undervaluation: The stock trades at 23.80x trailing PE but only 16.17x forward PE, a 32% compression that implies the market expects EPS to jump to the consensus $25.61. This forward multiple sits below the 20-25x range typical of quality healthcare compounders, suggesting the earnings ramp is not fully priced in.
- Strong relative outperformance and momentum: LH is up 27.44% YTD versus SPY's 11.70%, and its 3-month relative strength versus SPY is +23.37 percentage points. The 6-month gain of 21.94% also exceeds SPY's 17.44%, confirming sustained intermediate-term leadership despite a recent 1-month stall of -2.94%.
- Analyst consensus buy with upside: All 16 covering analysts rate the stock a buy (recommendation mean 1.76) with an average target of $343.31, implying 7.0% upside from $320.71. The high target of $385 implies 20% upside and reflects confidence in AI-driven margin expansion and specialty-test mix improvement.
Bearish
- Gross margin compression trend: Gross margin has declined from 29.66% in Q2 2025 to 28.77% in Q3 2025 to 26.52% in Q1 2026, a 314 basis point contraction over three quarters. This mix shift toward lower-margin testing and cost pressure could undermine the AI efficiency narrative if not reversed.
- Lumpy and weak free cash flow: Q1 2026 free cash flow was only $70.5M, weighed down by a $352.9M working-capital outflow and $121M of capex, versus $542.7M in Q2 2025. This volatility raises questions about the sustainability of cash generation to fund acquisitions, dividends, and debt reduction.
- Elevated leverage and debt repayment: Debt-to-equity stands at 0.836, and the company repaid $750M of debt in Q1 2026, indicating a meaningful leverage burden. With interest expense of $55.1M in Q1 2026, further rate pressure or earnings volatility could strain the balance sheet.
- Modest revenue growth limits re-rating: Q1 2026 revenue grew just 5.75% YoY to $3.538B, and quarterly revenue has been range-bound around $3.5B since Q2 2025. Without acceleration, the stock may struggle to justify multiple expansion beyond its current 23.80x trailing PE.
LH Technical Analysis
Labcorp is in a sustained uptrend, with the shares up 15.72% over the trailing year and 27.44% year-to-date, and the current price of $320.71 sits at roughly 78.4% of the 52-week range bounded by a low of $244.52 and a high of $341.80. That positioning near the upper end of the annual range signals persistent buyer conviction rather than a value dislocation, though it also means the stock is carrying momentum-driven expectations and has less cushion against a sentiment shift. The 52-week high of $341.80 is only about 6.6% above the current price, so the stock is consolidating just below a clear resistance ceiling rather than breaking into new high ground. Recent momentum has cooled even as the longer-term trend remains intact: the 1-month change is -2.94% versus the 3-month gain of 25.37%, a sharp deceleration that suggests the July-to-August advance is being digested. Notably, the 3-month relative strength versus SPY is +23.37 percentage points, far outpacing the 1-month relative strength of -1.98 points, confirming that Labcorp's outperformance was concentrated in the spring-to-summer window and has stalled into September. The 6-month change of +21.94% and YTD gain of +27.44% both exceed SPY's +17.44% and +11.70% over the same periods, so the intermediate trend remains decisively bullish despite the near-term stall. Key support rests at the 52-week low of $244.52, with the more immediate September pullback low near $306.96 acting as a first line of defense, while resistance is anchored at the $341.80 52-week high. A decisive breakout above $341.80 would confirm trend continuation and likely invite momentum buyers, whereas a breakdown below the $306-$307 area would threaten the intermediate uptrend and open the door toward the $280-$290 zone where the stock consolidated in July. With a beta of 0.851, Labcorp is roughly 15% less volatile than the broader market, which supports larger position sizing for risk-adjusted exposure but also means the stock may lag in sharp risk-on rallies.
Beta
0.85
0.85x market volatility
Max Drawdown
-15.2%
Largest decline past year
52-Week Range
$245-$342
Price range past year
Annual Return
+15.8%
Cumulative gain past year
| Period | LH Return | S&P 500 |
|---|---|---|
| 1m | -4.6% | +1.0% |
| 3m | +24.1% | +5.4% |
| 6m | +20.7% | +17.8% |
| 1y | +15.8% | +16.5% |
| ytd | +27.5% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LH Fundamental Analysis
Labcorp's revenue trajectory is steady and modestly improving, with Q1 2026 revenue of $3.538 billion growing 5.75% year-over-year against Q1 2025's $3.345 billion, and the sequential cadence through 2025 shows a stable base of roughly $3.5 billion per quarter (Q2 2025: $3.527 billion; Q3 2025: $3.564 billion; Q4 2025: $3.516 billion). The segment mix shows LabCorp Diagnostics contributing $2.762 billion and Biopharma Laboratory Services adding $780.6 million, meaning the diagnostics franchise remains the dominant growth engine at roughly 78% of revenue while the biopharma arm provides a smaller but strategically important specialty and clinical-research lever. Growth is not accelerating dramatically, but the consistency of mid-single-digit expansion, combined with raised full-year guidance tied to AI and robotics investments, supports a durable compounding narrative rather than a cyclical spike. Profitability is solid and improving: Q1 2026 net income was $277.8 million on a 7.85% net margin, up from $212.8 million and a 6.36% net margin in Q1 2025, while gross margin was 26.52% and operating margin 10.87%. Gross margin has compressed modestly from the 28.77% recorded in Q3 2025 and 29.66% in Q2 2025, reflecting mix shifts and cost pressure, but operating income rose to $387.2 million in Q1 2026 from $326.0 million a year earlier, showing that SG&A discipline and automation are offsetting gross-margin softness. The company's 10.87% operating margin is consistent with the low-double-digit profitability typical of scaled diagnostic lab operators, and the trend of expanding net income despite flattish gross margins is a positive signal for the AI-driven efficiency thesis. The balance sheet is healthy but carries meaningful leverage: debt-to-equity is 0.836, the current ratio is 1.424, and ROE is 10.17% with ROA at 5.53%, indicating adequate but not exceptional returns on capital. Free cash flow on a trailing-twelve-month basis is $1.384 billion, though quarterly FCF has been lumpy, ranging from $70.5 million in Q1 2026 to $542.7 million in Q2 2025, and Q1 2026 operating cash flow of $191.5 million was weighed down by a $352.9 million working-capital outflow and $121 million of capex. The company returned capital via $61.2 million of dividends and $98 million of buybacks in Q1 2026 while repaying $750 million of debt, demonstrating the capacity to fund operations, acquisitions ($202.2 million in Q1 2026), and shareholder returns internally, though the elevated debt load and working-capital swings warrant monitoring.
Quarterly Revenue
$3.5B
2026-03
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
26.5%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LH Overvalued?
Because Labcorp is solidly profitable with positive net income of $277.8 million in the most recent quarter and trailing EPS of $3.37, the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 23.80x versus a forward PE of 16.17x, a roughly 32% compression that implies the market expects meaningful earnings growth ahead, consistent with consensus EPS estimates of $25.61 for the forward period and the company's raised guidance. The PEG ratio of 1.28 suggests the stock is priced roughly in line with its growth rate, neither a bargain nor egregiously expensive on a growth-adjusted basis. Relative to the broader healthcare and diagnostics sector, Labcorp's 23.80x trailing PE and 1.50x PS ratio appear moderate, with the PS multiple well below the 5-6x range the stock commanded in 2021-2022 and the EV/EBITDA of 13.69x reflecting a reasonable earnings-based valuation. The forward PE of 16.17x is notably below the trailing multiple and below the roughly 20-25x range typical for quality healthcare compounders, suggesting the market is discounting execution risk or viewing the earnings ramp as already priced in. On a price-to-book basis of 2.42x and price-to-cash-flow of 12.72x, the stock is not trading at distressed levels, but the 1.15% dividend yield and 27.46% payout ratio indicate a balanced capital-return posture rather than a deep-value income profile. Historically, Labcorp's PE has ranged from the low teens during the 2021-2022 COVID-testing boom (9.9x-12.9x) to the high 20s and low 30s during earnings troughs (31.4x in Q4 2025, 33.3x in Q4 2024), so the current 23.80x sits in the middle-to-upper portion of its multi-year band. The PS ratio of 1.50x, by contrast, is near the low end of its historical range (which peaked above 6x in 2021-2023), reflecting both revenue growth and the market's more disciplined multiple discipline. The current valuation therefore embeds optimism about margin recovery and AI-driven efficiency but is not stretched relative to the company's own history, leaving room for re-rating if forward EPS estimates are met or exceeded.
PE
23.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 10x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Labcorp's financial and operational risks center on its gross margin compression and working-capital volatility. Gross margin fell from 29.66% in Q2 2025 to 26.52% in Q1 2026, a 314 basis point decline that reflects mix shifts toward lower-margin routine testing and cost pressure. Free cash flow is lumpy, with Q1 2026 FCF of just $70.5M versus $542.7M in Q2 2025, driven by a $352.9M working-capital outflow and $121M of capex. The company also carries meaningful leverage with a debt-to-equity of 0.836 and repaid $750M of debt in Q1 2026, while interest expense of $55.1M consumes a notable share of operating income. Revenue concentration in the diagnostics segment (78% of revenue at $2.762B in Q1 2026) means any volume softness in routine testing could disproportionately impact results, and the biopharma arm at $780.6M is not yet large enough to fully offset such a decline.
Market and competitive risks include valuation compression if the forward earnings ramp disappoints. At 23.80x trailing PE, the stock sits in the middle-to-upper portion of its historical band (which ranged from 9.9x-12.9x during the COVID boom to 31.4x-33.3x during earnings troughs), leaving room for multiple contraction if growth slows. The PS ratio of 1.50x is near the low end of its historical range, but the EV/EBITDA of 13.69x is not distressed. With a beta of 0.851, LH is less volatile than the market, but this also means it may lag in sharp risk-on rotations. Competitive disruption from the other national lab duopoly player, regulatory pressure on reimbursement rates, and macro sensitivity to healthcare utilization trends pose ongoing threats. Recent news highlights AI and robotics investments as a growth driver, but execution risk remains if these initiatives fail to deliver expected efficiencies.
In a worst-case scenario, a combination of gross margin compression continuing below 26%, revenue growth decelerating below 5%, and AI investments failing to yield margin expansion could trigger analyst downgrades and multiple compression. The stock could fall to the analyst low target of $293 (about 8.6% downside from $320.71) or even retest the 52-week low of $244.52, representing a 23.8% decline. A more severe scenario involving a recession that curbs healthcare utilization, combined with reimbursement cuts, could push the stock toward the $244-$250 range, implying a loss of 22-24% from current levels. The max drawdown over the past 180 days was -15.22%, but a fundamental deterioration could exceed that, especially given the stock's 27.44% YTD gain and elevated expectations.
FAQ
The most severe risk is gross margin compression, which has fallen from 29.66% in Q2 2025 to 26.52% in Q1 2026, a 314 basis point decline that could undermine profitability if the trend continues. Second is revenue concentration, with the diagnostics segment contributing 78% of revenue ($2.762B in Q1 2026), making the company vulnerable to volume softness in routine testing. Third is financial leverage, with a debt-to-equity of 0.836 and $55.1M in quarterly interest expense, which could strain the balance sheet if earnings decline. Fourth is valuation risk, as the stock trades at 23.80x trailing PE and has already gained 27.44% YTD, leaving limited cushion if growth disappoints or if the market de-rates healthcare stocks. Additionally, lumpy free cash flow (Q1 2026 FCF of $70.5M vs. $542.7M in Q2 2025) adds uncertainty to capital return sustainability.
The 12-month forecast has three scenarios: a base case (50% probability) with a target range of $330-$350, assuming 5-6% revenue growth and modest margin expansion; a bull case (30% probability) with a target range of $360-$385, driven by successful AI-driven margin expansion and multiple re-rating; and a bear case (20% probability) with a target range of $244-$293, reflecting gross margin compression and revenue deceleration. The base case is most likely, anchored by the analyst average target of $343.31 and consensus EPS of $25.61. The key assumption behind the base case is that operating margin improves to 11.2% and gross margin stabilizes around 26-27%. A breakout above the 52-week high of $341.80 would signal bull-case momentum, while a breakdown below $306-$307 would increase bear-case risk.
LH appears fairly valued to slightly undervalued on a forward basis. The trailing PE of 23.80x sits in the middle-to-upper portion of its historical range (9.9x-33.3x), but the forward PE of 16.17x is well below the 20-25x typical of quality healthcare compounders, implying the market expects significant earnings growth. The PS ratio of 1.50x is near the low end of its historical range (which peaked above 6x in 2021-2023), and the PEG ratio of 1.28 suggests the stock is priced in line with its growth rate. The EV/EBITDA of 13.69x is reasonable for a scaled diagnostics operator. The market is paying a fair price that embeds optimism about margin recovery and AI-driven efficiency, but is not stretched relative to the company's own history, leaving room for re-rating if forward EPS estimates of $25.61 are met or exceeded.
From a risk/reward perspective, LH is a reasonable buy for patient investors, with 7.0% upside to the average analyst target of $343.31 and 20% upside to the high target of $385, against 8.6% downside to the low target of $293. The forward PE of 16.17x provides a valuation cushion, and the 30.5% YoY net income growth in Q1 2026 demonstrates earnings momentum. However, the stock is up 27.44% YTD and trading just 6.6% below its 52-week high, so near-term upside may be limited. The biggest downside risk is continued gross margin compression, which fell to 26.52% in Q1 2026 from 29.66% in Q2 2025. It is a good buy for long-term investors comfortable with mid-single-digit revenue growth and a defensive healthcare profile, but short-term traders may find better entry points near the $306-$307 support level.
LH is better suited for long-term investment, with a suggested minimum holding period of 12-18 months. The company is in a steady growth phase with 5.75% YoY revenue growth, a 1.15% dividend yield, and a low beta of 0.851, which supports a buy-and-hold strategy. The earnings inflection and AI-driven margin expansion thesis will take several quarters to fully play out, and the forward PE discount to the trailing multiple suggests the market will reward execution over time. Short-term trading is less attractive given the stock's recent 1-month decline of 2.94% and its position 6.6% below the 52-week high, which limits near-term upside. The defensive healthcare characteristics and consistent free cash flow generation make it a suitable core holding for income and moderate growth, but investors should monitor quarterly gross margin trends and revenue growth to ensure the thesis remains intact.